Get the Stockscreener App
10.32
4.29%
-0.4631
Pre-market:
10.32
Polyrizon Ltd stock is traded at $10.32, with a volume of 2,024.
It is down -4.29% in the last 24 hours and down -28.13% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$10.78
Open:
$10.3
24h Volume:
2,024
Relative Volume:
0.03
Market Cap:
$24.79M
Revenue:
-
Net Income/Loss:
$-3.34M
P/E Ratio:
-3.8229
EPS:
-2.6995
Net Cash Flow:
$-10.54M
1W Performance:
-1.81%
1M Performance:
-28.13%
6M Performance:
-18.16%
1Y Performance:
+57.80%
1-Day Range:
$10.17
$10.47
1-Week Range:
$10.08
$11.00
52-Week Range:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
10.32 | 25.88M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon Files First-Half 2026 Results Showing Higher Assets and Wider Loss - TipRanks
A 9.99% ownership limit restricts exercise of Polyrizon (PLRZ) share purchase rights. - Stock Titan
First human trial gets approval as Polyrizon (PLRZ) reports a wider six-month loss. - Stock Titan
Polyrizon (PLRZ) Slides 2.20% to $10.66 as Shares Drift Toward $10.13 SupportIndex Put Call - siam.in
Polyrizon enrolls first patient in U.S. allergy blocker trial By Investing.com - Investing.com South Africa
Polyrizon enrolls first patient in U.S. allergy blocker trial - Investing.com
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker - The Manila Times
A drug-free nasal spray enters human testing for allergies. Polyrizon enrolled the first patient. - Stock Titan
Single investor clears new Polyrizon (PLRZ) shares to resell - Stock Titan
Biotech Polyrizon (PLRZ) completes new warrant funding - Stock Titan
Polyrizon (NASDAQ: PLRZ) Announces Offering of 232,500 Shares at $12.00 Plus 30,000 Pre-Funded Warrants - kalkinemedia.com
Polyrizon announces closing of registered direct offering - Medical Buyer
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement - TipRanks
Single investor funds new Polyrizon (PLRZ) cash raise - Stock Titan
Polyrizon Ltd. (PLRZ) Stock: Company Closes $4 Million Deal With Institutional Investor - blockonomi.com
Polyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement - Quiver Quantitative
One investor puts about $4 million into Polyrizon - Stock Titan
$4M funding deal gives Polyrizon (PLRZ) investor long-term warrant rights - stocktitan.net
Polyrizon raises $4 million in registered direct offering By Investing.com - Investing.com Nigeria
Polyrizon raises $4 million in registered direct offering - Investing.com
One investor agreed to buy Polyrizon shares and warrants; proceeds are expected at about $4 million. - Stock Titan
Polyrizon (PLRZ) Holds Near $12.56: Small-Cap Pharma Stock Faces Key Technical TestSymmetrical Triangle - dars.gov.et
Polyrizon completes contracting for allergy blocker trial sites By Investing.com - Investing.com South Africa
Polyrizon Tumbles on Clinical Studies - baystreet.ca
Polyrizon completes contracting for allergy blocker trial sites - Investing.com
Polyrizon Completes U.S. Clinical Site Contracting for NASARIX Allergy Blocker Study - Quiver Quantitative
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study - FinancialContent
Polyrizon (PLRZ) Trading: Ends Down by 1.40% at $10.53 in Latest Trading; the Current Price Sits Inside the Supplied Technical Range in the Latest SessionAnalyst Downgrade Signals - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingWyckoff Accumulation - vinanet.vn
Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study - TipRanks
Polyrizon (PLRZ) lines up sites for 120-patient allergy study - Stock Titan
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com South Africa
Polyrizon Completes Site Contracting for NASARIX™ Seasonal Allergic Rhinitis Study - Quiver Quantitative
Polyrizon's planned allergy study will compare its spray with saline in up to 120 patients - Stock Titan
Polyrizon (PLRZ) Close and Levels: Records a 5.65% Decrease to $10.36 for the Current Session; Nearby Levels: the Current Price Sits Inside the Supplied Technical Range in the Available RecordRectangle Pattern - vinanet.vn
Polyrizon Ltd. (PLRZ) Gains 2.14% to $10.98, Holding Support Amid Biotech InterestTPO Profile - vinanet.vn
Polyrizon Ltd. (PLRZ): MMCAP group discloses 9.6% beneficial stake - Stock Titan
DISCLOSED: Insiders Are Now Buying *This Stock* Sootoday.com (Je9ZHM0WVP) - Mshale
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Ltd. (PLRZ) Slips 2.24% as Shares Test Key Support Zone Near $10.76Stock Picks - dars.gov.et
PLRZ.O PE Ratio & Valuation, Is PLRZ.O Overvalued - Intellectia AI
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Polyrizon Ltd (PLRZ) Earnings Date & Reports & Earnings News - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Cash Flow - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Ltd (PLRZ) Balance Sheet - TradingKey
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Polyrizon Ltd Stock (PLRZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carmel Liron | Director |
Mar 31 '26 |
Sale |
12.36 |
942 |
11,643 |
3,127 |
| Adler Oz | Director |
Mar 31 '26 |
Sale |
12.05 |
3,292 |
39,669 |
19,850 |
| Carmel Liron | Director |
Mar 30 '26 |
Sale |
11.00 |
100 |
1,100 |
4,069 |
| Izraeli Tomer | Chief Executive Officer |
Mar 30 '26 |
Sale |
10.90 |
3,900 |
42,510 |
32,012 |
| Turgeman Tidhar | Chief Technology Officer |
Mar 30 '26 |
Sale |
10.90 |
2,917 |
31,795 |
17,518 |
1.48%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):